Publications by Professor Gareth Veal - ePrints

Browsing publications by Professor Gareth Veal.

Newcastle Authors	Title	Year
Professor Gareth Veal	A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)	2024
Dr Hayden Bell Dr Helen Blair Samantha Jepson Gosling Dr Martin Galler Dan Astley et al.	Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	2024
Professor Gareth Veal	A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer	2023
Julieann Sludden Professor Gareth Veal Professor Ruth Plummer	A Phase 1/2A trial of idroxioleic acid: First-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma	2023
Professor Gareth Veal Professor Steve Wedge Dr Christopher Bacon Professor Philip Sloan Professor Alastair Greystoke et al.	A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer	2023
Professor Gareth Veal	Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials	2023
Dr Shelby Barnett Dr Martin Galler Dr David Jamieson Professor Gareth Veal	Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report	2023
Dr Shelby Barnett Professor Deborah Tweddle Professor Gareth Veal	Generation of evidence-based carboplatin dosing guidelines for neonates and infants	2023
Dr Shelby Barnett Professor Gareth Veal	Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk	2023
Professor Gareth Veal	Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial	2023
Julie Errington Dr Shelby Barnett Professor Gareth Veal	Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma	2023
Dr Shelby Barnett Professor Gareth Veal	A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in children	2022
Dr Shelby Barnett Dr Vickyanne Carruthers Professor Deborah Tweddle Professor Gareth Veal	Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance	2022
Dr Vickyanne Carruthers Dr Shelby Barnett Dr Tasnim Arif Professor Gareth Veal	Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series	2022
Dr Oladipo Idowu Professor Gareth Veal Dr David Jamieson	Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum	2022
Dr Shelby Barnett Professor Gareth Veal	Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations	2022
Professor Gareth Veal	Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04)	2022
Dr Tobias Menne Professor Julie Irving Professor Ruth Plummer Dr Geoff Shenton Professor Gareth Veal et al.	Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial	2022
Dr Shelby Barnett Professor Deborah Tweddle Professor Gareth Veal	Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients	2022
Melanie Griffin Dr Claire Jennings Professor Gareth Veal	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemia	2021
Dr Catherine Gowland Philip Berry Julie Errington Professor Gareth Veal	Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study	2021
Dr Shelby Barnett Professor Gareth Veal	Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom	2021
Dr Shelby Barnett Julie Errington Julieann Sludden Dr David Jamieson Professor Gareth Veal et al.	Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population	2021
Professor Gareth Veal Professor Deborah Tweddle Julie Errington	Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: A randomized crossover clinical trial	2021
Eve Roberts Dr Jasper Mogg Professor Gareth Veal	Investigating current practices in renal function measurement and carboplatin dosing in children with cancer – a UK perspective	2020
Dr Karen Barker Philip Berry Professor Gareth Veal Dr John Anderson	In vivo Modelling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis	2019
Suriyon Uitrakul Dr Claire Hutton Professor Gareth Veal Dr David Jamieson	A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells	2019
Dr Marina Danilenko Dr Kirsty Hodgson Monique Zangarini Professor Gareth Veal Professor Neil Rajan et al.	Diverse assays from a single skin punch biopsy to assess topical drug intervention	2019
Professor Gareth Veal	Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function	2019
Liz Matheson Huw Thomas Marian Case Dr Helen Blair Rosanna Jackson et al.	Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM	2019
Dr Rosanna Jackson Philip Berry Julie Errington Professor Julie Irving Professor Gareth Veal et al.	Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia - a report from the UKALL 2011 trial	2019
Professor Gareth Veal Philip Berry	Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste	2019
Professor Gareth Veal Dr Edward Amankwatia	Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities	2019
Professor Gareth Veal	Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition	2019
Professor Gareth Veal Julie Errington	Population pharmacokinetics of carboplatin, etoposide and melphalan in children: A re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function	2019
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Calum Kirk Dr Katrina Wood et al.	Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma	2019
Professor Gareth Veal Julie Errington Dr Leigh McDonald Professor Deborah Tweddle	The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression	2019
Professor Ruth Plummer Professor Steve Wedge Professor Gareth Veal	A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours	2018
Professor Gareth Veal	Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence	2018
Professor Gareth Veal	Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss	2018
Dr Marina Danilenko Elaine Stamp Dr Deborah Stocken Monique Zangarini Amy Cranston et al.	Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib	2018
Monique Zangarini Philip Berry Professor Gareth Veal	Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts	2018
Dr Lynsey McKenzie Hasan Issa Sandeep Potluri Dr Helen Blair Asmida Isa et al.	The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation	2018
Professor Gareth Veal	The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients	2018
Professor Gareth Veal	Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report	2018
Dr Britta Vormoor Professor Gareth Veal Melanie Griffin Professor Julie Irving Lynne Minto et al.	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia	2017
Monique Zangarini Philip Berry Julieann Sludden Professor Gareth Veal	Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma	2017
Monique Zangarini Professor Neil Rajan Dr Marina Danilenko Philip Berry Professor Gareth Veal et al.	Development and validation of LC–MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors	2017
Professor Gareth Veal Dr David Jamieson Katja Kuver	Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial	2017
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Dr Katrina Wood Professor Gareth Veal et al.	In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma	2017
Professor Gareth Veal Carine Boue Charlotte Lecour Annette Otto Maryam Rastegari et al.	Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey	2017
Professor Gareth Veal Julie Errington	Adaptive dosing of anticancer drugs in neonates – facilitating evidence-based dosing regimens	2016
Professor Gareth Veal Julieann Sludden Dr David Jamieson Julie Errington Dr Ghada Malik et al.	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma	2016
Chris Walsh Dr Jennifer Bonner Professor Alan Boddy Professor Gareth Veal	Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer	2016
Julie Errington Dr Ghada Malik Lisa Price Professor Gareth Veal	Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK	2016
Rosanna Jackson Professor Julie Irving Professor Gareth Veal	Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia	2016
Professor Gareth Veal	Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long term infusion in combination with IL-2	2016
Dr Vikram Gota Professor Gareth Veal	Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.	2016
Professor Gareth Veal Julie Errington Dr James Hayden Professor Deborah Tweddle	Carboplatin therapeutic monitoring in preterm and full-term neonates	2015
Professor Gareth Veal Julie Errington Dr James Hayden Professor Deborah Tweddle	Carboplatin therapeutic monitoring in preterm and full-term neonates	2015
Professor Gareth Veal Julie Errington Professor Deborah Tweddle	Therapeutic drug monitoring approaches to the treatment of preterm and full-term neonates with cancer - A UK experience	2015
Professor Gareth Veal	Blood volumes in paediatric clinical trials: a review of current regulations and guidance for research studies	2014
Dr Chris Hill Julie Errington Dr Ghada Malik Professor Alan Boddy Professor Gareth Veal et al.	Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer	2014
Professor Gareth Veal Dr Pamela Kearns	Defining a Target Intra-Cerebrospinal Fluid Steady State Etoposide Concentration [CSF Etoposide) for Phase I Study in Children with Leptomeningeal Metastasis (LM): Intrepid, A First in Man Study	2014
Professor Gareth Veal Dr David Walker	Etoposide Pharmacokinetics Following Intra-Cerebrospinal Fluid Administation in Patients with Leptomeningeal Metastases	2014
Professor Gareth Veal	Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib	2014
Professor Gareth Veal	Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics	2014
Professor Gareth Veal	Review of therapeutic drug monitoring of anticancer drugs part 2 – Targeted therapies	2014
Professor Gareth Veal	Therapeutic drug monitoring in cancer – Are we missing a trick?	2014
Professor Gareth Veal Julie Errington Sophie Rowbotham Nicola Illingworth Dr Ghada Malik et al.	Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma	2013
Christopher Hill Dr David Jamieson Huw Thomas Dr Colin Brown Professor Alan Boddy et al.	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo	2013
Professor Gareth Veal Julie Errington Dr Ghada Malik Dr Chris Hill Professor Alan Boddy et al.	Investigating the pharmacokinetics and dosing of anticancer drugs in infants and young children	2013
Professor Gareth Veal	Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial	2012
Professor Gareth Veal Professor Alan Boddy	Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring	2012
Professor Gareth Veal Professor Alan Boddy	Chemotherapy in newborns and preterm babies	2012
Professor Isabella Orienti Professor Gareth Veal	Novel micelles based on amphiphilic branched PEG as carriers for fenretinide	2012
Dr Caroline Bridgens Professor Gareth Veal Dr Chris Redfern Dr Jane Renwick	Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold	2012
Professor Ann Daly Professor Gareth Veal Dr David Jamieson Dr Sally Coulthard	Pharmacogenomics research at Newcastle University	2012
Dr Caroline Bridgens Professor Gareth Veal Dr Chris Redfern Dr Jane Renwick	Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates	2012
Dr Jane Renwick Shaun Martin Nicola Illingworth Dr David Jamieson Professor Penny Lovat et al.	The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide	2012
Dr Emma Meczes Huw Thomas Professor Richard Edmondson Professor Gareth Veal Professor Alan Boddy et al.	Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours	2012
Professor Alan Boddy Professor Ann Daly Professor Gareth Veal	Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases	2011
Julie Errington Professor Alan Boddy Professor Gareth Veal Mike Cole	Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy	2011
Julie Errington Professor Alan Boddy Professor Gareth Veal Mike Cole	Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients	2011
Dr Caroline Bridgens Professor Gareth Veal Dr Chris Redfern Dr Jane Renwick	Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates	2011
Dr Caroline Bridgens Professor Gareth Veal Dr Chris Redfern Dr Jane Renwick	Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26)	2011
Professor Gareth Veal	Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines	2010
Professor Gareth Veal	Clinical pharmacology in the adolescent oncology patient	2010
Mike Cole Professor Alan Boddy Professor Gareth Veal	Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate	2010
Bertrand Girard Professor Gareth Veal	Oxazaphosphorines: New therapeutic strategies for an old class of drugs	2010
Professor Gareth Veal Julie Errington Professor Andrew Pearson Professor Alan Boddy	Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients	2010
Dr Jane Renwick Dr Ross Flockhart Professor Gareth Veal Professor Penny Lovat Dr Chris Redfern et al.	Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells	2010
Sophie Rowbotham Professor Alan Boddy Dr Chris Redfern Professor Gareth Veal Professor Ann Daly et al.	Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation	2010
Sophie Rowbotham Professor Ann Daly Professor Gareth Veal Professor Alan Boddy	Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans	2010
Dr Malcolm Coulthard Mike Cole Professor Gareth Veal Dr Michael Keir	Human renal function maturation: a quantitative description using weight and postmenstrual age	2009
Julie Errington Professor Alan Boddy Professor Gareth Veal	Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma	2009
Mike Cole Professor Alan Boddy Dr Michael Keir Professor Gareth Veal	Estimation of renal function and its potential impact on carboplatin dosing in children with cancer	2008
Dr Jane Renwick Professor Gareth Veal Dr Chris Redfern	Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: Potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells	2008
Professor Gareth Veal Professor Alan Boddy	Population pharmacokinetic investigation of actinomycin D in children and young adults	2008
Mike Cole Annie Parry Dr Michael Reid Professor Alan Boddy Professor Gareth Veal et al.	A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer	2007
Professor Gareth Veal Julie Errington Dr Michael Tilby Professor Alan Boddy	Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours	2007
Professor Alan Boddy Melanie Griffin Julie Errington Professor Gareth Veal	Dosing of cancer patients with low or absent renal function	2007
Dr Michael Keir Mike Cole Annie Parry Professor Alan Boddy Professor Gareth Veal et al.	Estimating glomerular filtration rate in children with cancer - Impact of methodology on carboplatin dosing	2007
Dr Jane Renwick Gordon Taylor Huw Thomas Professor Alan Boddy Dr Chris Redfern et al.	Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo	2007
Professor Gareth Veal Mike Cole Geoffrey Taylor Julie Errington Professor Alan Boddy et al.	Pharmacogenetics and metabolism of cyclophosphamide in paediatric cancer patients	2007
Professor Gareth Veal Mike Cole Julie Errington Professor Alan Boddy	Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group	2007
Professor Gareth Veal Sophie Rowbotham Professor Alan Boddy	Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma	2007
Dr Jane Renwick Professor Gareth Veal Dr Chris Redfern Professor Penny Lovat	Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours	2007
Professor Gareth Veal Julie Errington Huw Thomas Professor Alan Boddy	Biliary excretion of etoposide in children with cancer	2006
Professor Gareth Veal	Enhanced antitumor activity of P450 prodrug-based gene therapy using the low K_m cyclophosphamide 4-hydroxylase P450 2B11	2006
Mike Cole Professor Alan Boddy Dr Pamela Kearns Lisa Price Annie Parry et al.	Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?	2006
Dr Jane Renwick Dr Chris Redfern Professor Gareth Veal	13-cis Retinoic acid and isomerisation in paediatric oncology - Is changing shape the key to success?	2005
Dr Jane Renwick Professor Alan Boddy Dr Chris Redfern Professor Andrew Pearson Professor Gareth Veal et al.	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells	2005
Professor Gareth Veal Mike Cole Julie Errington Annie Parry Dr Juliet Hale et al.	Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group study	2005
Professor Gareth Veal Dr Michael Tilby	A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia	2004
Mike Cole Annie Parry Dr Michael Keir Professor Andrew Pearson Professor Alan Boddy et al.	Estimation of glomerular filtration rate in paediatric cancer patients using ⁵¹CR-EDTA population pharmacokinetics	2004
Professor Gareth Veal Professor Alan Boddy	Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy	2004
Professor Gareth Veal Dr Sally Coulthard Professor Alan Boddy	Chemotherapy individualization	2003
Professor Gareth Veal	Clinical and cellular pharmacology in relation to solid tumours of childhood	2003
Professor Gareth Veal Julie Errington Julieann Sludden Melanie Griffin Annie Parry et al.	Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry	2003
Julie Errington Professor Gareth Veal Julieann Sludden Melanie Griffin Professor Andrew Pearson et al.	Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry	2003
Justin Armstrong Professor Gareth Veal Dr Chris Redfern Professor Alan Boddy	Effects of ketoconazole and acitretin on retinoid isomerisation and metabolism in neuroblastoma	2003
Professor Gareth Veal Julie Errington Professor Andrew Pearson Professor Alan Boddy	Poster Presentation: Oxidative metabolism of 13-cis-retinoic acid in children with neuroblastoma	2003
Dr Birju Rana Professor Gareth Veal Professor Andrew Pearson Dr Chris Redfern	Retinoid X receptors and retinoid response in neuroblastoma cells	2002
Professor Gareth Veal Julie Errington Dr Chris Redfern Professor Andrew Pearson Professor Alan Boddy et al.	Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells	2002
Dr Birju Rana Professor Gareth Veal Professor Andrew Pearson Dr Chris Redfern	Retinoid X receptors and retinoid response in neuroblastoma cells	2002
Professor Gareth Veal Melanie Griffin Annie Parry Dr Juliet Hale Professor Andrew Pearson et al.	A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin	2001
Professor Gareth Veal Dr Cinera Dias Annie Parry Julie Errington Dr Juliet Hale et al.	Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy	2001
Professor Gareth Veal Julie Errington Dr Chris Redfern Professor Andrew Pearson Professor Alan Boddy et al.	Influence of retinoid isomerisation on the cellular activity of 13-cis retinoic acid in neuroblastoma	2001
Professor Gareth Veal Dr Cinera Dias Professor Alan Boddy Annie Parry Dr Juliet Hale et al.	In vitro/in vivo correlations of cisplatin-DNA adduct levels in leucocytes of children	2000
Professor Gareth Veal Professor Alan Boddy Huw Thomas Annie Parry Professor Andrew Pearson et al.	Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy	1999
Professor Gareth Veal	Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro	1998